Through serendipity, science, and rigor, SpringWorks Therapeutics, a targeted oncology company, marks success with the first FDA-approved treatment for Desmoid Tumor.
Mrinal M. Gounder, MD, a sarcoma oncologist at Memorial Sloan Kettering Cancer Center and lead investigator of the phase 3 DeFi trial of nirogacestat in desmoid tumors, discusses the drug's recent FDA approval and potential impacts on desmoid tumor treatment going forward.
SpringWorks Therapeutics drug for treating adult patients with a type of rare noncancerous soft-tissue tumor will be sold in the US at a list price of $29,000 for a 30-day supply.